Vin is a serial entrepreneur with extensive experience in the healthcare industry: 

• Founder & former CEO, Next Healthcare Inc. 
• Co-founder, MaxCyte Inc. – Nasdaq (MXCT) – $1.5B market cap 
• Global director, cell therapy – ThermoFisher Scientific 

Vin earned his B.S. in electrical engineering at Rutgers University, an M.S. in biomedical engineering at Rensselaer Polytechnic Institute, and an MBA at Johns Hopkins University. 

Dane is a seasoned executive with deep experience in finance and accounting, SEC compliance, and corporate governance: 

• Former CFO of EntreMed, Inc., New Generation Biofuels, Inc., and RegeneRx Biopharmaceuticals, Inc. 
• Most recently CFO with Seneca Biopharma Inc., which merged with Leading Biosciences Inc.   

Dane earned his B.S. in business administration at the University of Maryland.

Dr. Tom Chittenden, a GIGA Society Fellow with over 25 years of experience in experimental and theoretical research, leads scientific operations for BullFrog AI. He holds an Honorary Professorship of AI in Biomedicine at the Digital Environment Research Institute, Queen Mary University of London.

Over the past decade, Tom has led AI-driven R&D initiatives targeting a range of diseases including cardiovascular disease, cancer, COVID-19, NASH, Alzheimer’s, and Parkinson’s. His focus includes quantum machine learning, exascale causal AI computing, systems biology, and in-silico phenotype projection to decipher cellular behavior and advance drug discovery and development.

• Lecturer on Pediatrics in the Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School.
• Visiting Lecturer in the Department of Biological Engineering at the Massachusetts Institute of Technology.
• Published in top-tier scientific journals, including Nature and Science.
• Chief Scientific Officer and President of R&D at BioAI Health.
• Chief Technology Officer and President of AI R&D at HiberCell.
• Chief Technology Officer, President, and Founding Director of the Genuity AI Research Institute at Genuity Science.
• Chairman, President, and Chief Scientist at the Complex Biological Systems Alliance.
• BIG AI Excellence Award Winner in 2021.
• Top 100 Pioneer in Drug Discovery and Advanced Healthcare by Deep Knowledge Analytics and Forbes Magazine, 2019.

Prof. Chittenden is globally recognized as a leading authority in causal AI/SciML within the biomedical sciences. An Accredited Professional Statistician™ with the American Statistical Association, he holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Statistics from the University of Oxford.

His postdoctoral training encompasses:

• Experimental investigations in molecular and cellular cardiology at the Dartmouth Medical School.
•  Biostatistics and computational biology at the Dana‐Farber Cancer Institute and the Harvard School of Public Health.
•  Computational statistics and statistical machine learning at the University of Oxford.

JT has 30+ years of experience leveraging IT services for business, during which he developed expertise that includes providing better security through custom application development and automating cumbersome business practices: 

• Founder of Delmarva Group, LLC
• Director of IT architecture for Day and Zimmerman 

Thomas has 20+ years of industry experience in R&D and business development, delivering exceptional results throughout his career: 

• Senior VP of R&D at Seneca Biopharma, overseeing the development of the company’s stem cell-based therapeutics platform 
• 9 U.S. patents granted and multiple foreign patents in stem cells and regenerative medicine

Thomas earned his Ph.D. in genetics at the University of Illinois College of Medicine.

Kristin is a highly accomplished researcher and assistant professor of medicine, psychiatry, and pharmacology at Johns Hopkins University’s School of Medicine.

Her research is focused on neuropsychiatric drug development with a precision medicine approach to the treatment of mental illness. 

Kristin earned her B.S. in premedicine at Pennsylvania State University and a Ph.D. in clinical pharmaceutical sciences at the University of Pittsburgh. 

David is an eminent drug development expert with a deep well of expertise drawn from decades of experience: 

• Chief medical officer with Neuralstem/Seneca Biosciences Corporation 
• Chief medical officer with Vericel Corporation 
• Senior VP of clinical sciences with Takeda Global Research and Development 

David earned his M.D. with distinction at the University of Michigan Medical School.

Toby is an experienced business development professional with 18+ years in sales, client engagement, and consulting delivery for the life sciences and biotechnology industry. He has an extensive technical background:  

• Bioinformatics and biochemistry 
• Applied experience in real-world data
• NLP and AI software 
• Analytical consulting  

Toby earned an M.S. in cell and molecular biology at San Francisco State University and another M.S. in at UCLA.

Enrique is a passionate scientist committed to advancing the discovery and development of therapeutics through the use of machine learning and predictive analytics. With extensive experience in early stage drug discovery, data science, and financial knowledge, he provides a unique and advantageous perspective to biotechnology strategic decision making. His extensive technical background includes:   

• Development of sophisticated predictive models with biological data 
• Deployment and management of predictive models in the cloud
• Large scale deployment of bioinformatic pipelines for processing genomic data 

Enrique earned his Ph.D. in biological and biomedical sciences at Harvard Medical School.